Still No Benefit of IP Chemo for Ovarian Cancer
April 24, 2019 5:00 pmBy Charles Bankhead
No PFS or OS benefit, more toxicity with IP verses IV regimens
Final results of a highly anticipated randomized trial failed to show a survival benefit with intraperitoneal (IP) chemotherapy in patients with newly diagnosed advanced ovarian … Read more